Promising combo for rare lymphoma hits roadblock: trial ends early
NCT ID NCT03547700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the highest safe dose could not be determined. The goal was to see if the drugs could shrink tumors, but results are limited due to early termination.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T CELL, PERIPHERAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Center (Wayne State University)
Detroit, Michigan, 48201, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.